 |
|
eculizumab
A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | Alexion
monoclonal antibody 5G1.1
monoclonal antibody anti-C5 | | | | US brand name: | | Soliris | | | | Abbreviation: | | h5G1.1 | | |
|
|
